Hewitt Lecture 2018: "Paying for Innovation in the Coming Age of Breakthrough Therapies"

Life sciences companies are developing higher-cost therapies to treat rare diseases with smaller patient populations. Effective reimbursement strategies will allow innovation to continue and expand patient access to new life-changing therapies. Join us for an evening with Mark McClellan, Duke University Professor and former FDA Commissioner.